Evidence map›Paper›PMID 35354052›Full record

ArticleCell reports2022

Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans.

Isabella Huettner, Stefanie A Krumm, Sonia Serna, Katarzyna Brzezicka, Serena Monaco, Samuel Walpole, Angela van Diepen, Fiona Allan, Thomas Hicks, Simon Kimuda and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Isabella HuettnerDepartment of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
Stefanie A KrummDepartment of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
Sonia SernaGlycotechnology Laboratory, Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 San Sebastian, Spain.
Katarzyna BrzezickaGlycotechnology Laboratory, Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 San Sebastian, Spain.
Serena MonacoSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk NR4 7TJ, UK.
Samuel WalpoleSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk NR4 7TJ, UK.
Angela van DiepenDepartment of Parasitology, Leiden University Medical Center, Leiden, the Netherlands.
Fiona AllanDepartment of Life Sciences, Natural History Museum, Cromwell Road, London, UK.
Thomas HicksSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk NR4 7TJ, UK.
Simon KimudaDepartment of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
Aidan M EmeryDepartment of Life Sciences, Natural History Museum, Cromwell Road, London, UK.
IAVI Protocol C Investigators & The IAVI African HIV Research Network
Elise LandaisInternational AIDS Vaccine Initiative Neutralizing Antibody Center, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, New York, NY 10004, USA.
Cornelis H HokkeDepartment of Parasitology, Leiden University Medical Center, Leiden, the Netherlands.
Jesus AnguloSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk NR4 7TJ, UK; Instituto de Investigaciones Químicas (CSIC-US), Avda. Américo Vespucio, 49, 41092 Sevilla, Spain.
Niels ReichardtGlycotechnology Laboratory, Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 San Sebastian, Spain; CIBER-BBN, Paseo Miramón 182, 20009 San Sebastian, Spain.
Katie J DooresDepartment of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK. Electronic address: katie.doores@kcl.ac.uk.
University of East Anglia · GBKing's College London · GBCIC biomaGUNE · ESLeiden University Medical Center · NLInternational AIDS Vaccine Initiative · USNatural History Museum · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M011216/1Biotechnology and Biological Sciences Research Council BB/P010660/1Department of HealthMedical Research Council MR/K024426/1Wellcome TrustWellcome Trust 104958/Z/14/Z
6 · The paper itself

Abstract

The HIV-1 Envelope glycoprotein (Env) is the sole target for broadly neutralizing antibodies (bnAbs). Env is heavily glycosylated with host-derived N-glycans, and many bnAbs bind to, or are dependent upon, Env glycans for neutralization. Although glycan-binding bnAbs are frequently detected in HIV-infected individuals, attempts to elicit them have been unsuccessful because of the poor immunogenicity of Env N-glycans. Here, we report cross-reactivity of glycan-binding bnAbs with self- and non-self N-glycans and glycoprotein antigens from different life-stages of Schistosoma mansoni. Using the IAVI Protocol C HIV infection cohort, we examine the relationship between S. mansoni seropositivity and development of bnAbs targeting glycan-dependent epitopes. We show that the unmutated common ancestor of the N332/V3-specific bnAb lineage PCDN76, isolated from an HIV-infected donor with S. mansoni seropositivity, binds to S. mansoni cercariae while lacking reactivity to gp120. Overall, these results present a strategy for elicitation of glycan-reactive bnAbs which could be exploited in HIV-1 vaccine development.

Indexed as

HIV-1HIV InfectionsParasitesAnimalsAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesHumansPolysaccharidesAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesPolysaccharidesCP: Immunologyglycan epitopeHIV-1neutralizing antibodySchisotosoma mansonivaccine

Identifiers

PMID35354052
PMCPMC10073069
OpenAlexW4220705358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.